Osteoporosis in chronic kidney disease (CKD) is also referred to as ‘CKD with low bone mineral density (BMD)’, because the cause of low BMD in CKD includes chronic kidney disease-mineral bone disorders (CKD-MBD) such as secondary hyperparathyroidism, osteomalacia, and adynamic bone disease. Diagnostic methods of osteoporosis in CKD include FRAX®, BMD, and bone turnover markers as well as CKD-MBD biochemical parameters- calcium, P, alkaline phosphatase, PTH, and 25(OH)D3. The management of osteoporosis in CKD prioritizes CKD-MBD management over selection of bone anti-resorptive agents or osteo- anabolic agents according to clinical and laboratory findings. (Korean J Med 2020;95:89-94)